Indeed, the introduction of immunotherapy has revolutionized the therapeutic approach to melanoma and monoclonal antibodies targeting the PD-1/PD-L1 axis have significantly prolonged patient survival (2–5, 31). This evidence concerns the gene PDCD1 and melanoma.